Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials

Psoriatic Arthritis

Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of the Phase 3, Randomized, Placebo-Controlled SOLSTICE Study

Arthritis Rheumatol

Ogdie A, Merola JF, Mease PJ, Ritchlin CT, Scher JU, Lafferty KP, Chan D, Chakravarty SD, Langholff W, Wang Y, Shao J, Krol Y, Gottlieb AB

doi: 10.1002/art.70092

Psoriatic Arthritis

Relationship of radiographic progression status to low disease activity in patients with psoriatic arthritis receiving secukinumab treatment for two years

Rheumatology (Oxford)

Mease PJ, Coates LC, Gaillez C, Shew A, Bao W, Ritchlin CT

doi: 10.1093/rheumatology/keaf488

Rheumatoid Arthritis

Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials

Semin Arthritis Rheum

Dieudé P, Sparks JA, Fischer A, Chen L, Lozenski K, Dahan S, Chaballa M, Little W

doi: 10.1016/j.semarthrit.2025.152795

Gout

Colchicine concentrations and relationship with colchicine efficacy and adverse events; post-hoc analysis of a randomised clinical trial of colchicine for gout flare prophylaxis

Arthritis Care Res (Hoboken)

Stamp LK, Horne A, Mihov B, Drake J, Haslett J, Chapman P, Wright DF, Frampton C, Dalbeth N

doi: 10.1002/acr.25548

Psoriatic Arthritis

Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial

Nat Med

McInnes IB, Coates LC, Mease PJ, Ogdie A, Kavanaugh A, Eder L, Schett G, Kivitz A, McGonagle D, Brennan N, Godwood A, Cullen E, Reich K, Ritchlin CT, Merola JF

doi: 10.1038/s41591-025-03971-6

Psoriatic Arthritis

Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study

Ann Rheum Dis

Mease PJ, Ritchlin CT, Coates LC, Kollmeier AP, Zhou B, Jiang Y, Bensley K, Im K, Batra R, Chakravarty SD, Rahman P, van der Heijde D

doi: 10.1016/j.ard.2025.08.006

Psoriatic Arthritis

Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies

RMD Open

Coates LC, Blanco R, Behrens F, Ogdie A, Van den Bosch F, Ranza R, Klionsky Y, Soliman AM, Chen M, Coombs D, Shi L, Urbanik JR, Iyile T, Lippe R, Gossec L

doi: 10.1136/rmdopen-2025-005522

Psoriatic Arthritis

Comparison of radiographic spinal changes and their progression in patients with axial spondyloarthritis vs. psoriatic arthritis with inflammatory axial involvement

Arthritis Res Ther

Sewerin P, Redeker I, Lavda E, Supp G, Sieghart D, Aletaha D, Mandl P, Kiefer D, Baraliakos X

doi: 10.1186/s13075-025-03692-8

Psoriatic Arthritis

The Impact of Early Attainment of Minimal Disease Activity on Radiographic Outcomes: A Real-World Longitudinal Cohort Study in Psoriatic Arthritis

J Rheumatol

Koc GH, Kok MR, Snoeck Henkemans SVJ, Luime JJ, Tchetverikov I, van der Kaap JH, Baudoin P, Kok P, Goekoop-Ruiterman YPM, Vos PAJM, van Oosterhout M, Korswagen LA, Dolhain RJEM, Vis M

doi: 10.3899/jrheum.2024-1162

Related content

Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of the Phase 3, Randomized, Placebo-Controlled SOLSTICE Study

Relationship of radiographic progression status to low disease activity in patients with psoriatic arthritis receiving secukinumab treatment for two years

Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials

Colchicine concentrations and relationship with colchicine efficacy and adverse events; post-hoc analysis of a randomised clinical trial of colchicine for gout flare prophylaxis

Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial

Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study

Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies

Comparison of radiographic spinal changes and their progression in patients with axial spondyloarthritis vs. psoriatic arthritis with inflammatory axial involvement

The Impact of Early Attainment of Minimal Disease Activity on Radiographic Outcomes: A Real-World Longitudinal Cohort Study in Psoriatic Arthritis